F J Giles

Summary

Publications

  1. ncbi request reprint The role of inflammation in leukaemia
    Francis J Giles
    Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
    Adv Exp Med Biol 816:335-60. 2014
  2. pmc Targeting HSP90 for cancer therapy
    D Mahalingam
    Institute for Drug Development, Cancer Research and Therapy Centre at the University of Texas Health Science Centre, San Antonio, TX 78229, USA
    Br J Cancer 100:1523-9. 2009
  3. pmc Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
    Ronan Swords
    Institute for Drug Development, Cancer Therapy and Research Centre, University of Texas Health Science Centre at San Antonio, 7979 Wurzbach Road, San Antonio, TX 78229, USA
    Drug Des Devel Ther 3:89-101. 2009
  4. doi request reprint Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
    F J Giles
    HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, Dublin, Ireland
    Leukemia 27:1310-5. 2013
  5. doi request reprint MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia
    F J Giles
    HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College Dublin, Galway, Ireland
    Leukemia 27:113-7. 2013
  6. doi request reprint Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    F J Giles
    HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College, Dublin, Ireland
    Leukemia 27:107-12. 2013
  7. doi request reprint Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia
    Francis Giles
    HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, Dublin, Ireland
    Eur J Clin Invest 42:1016-26. 2012
  8. doi request reprint Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
    F J Giles
    HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, University Road, Galway, Ireland
    Leukemia 26:959-62. 2012
  9. ncbi request reprint Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Box 428, Houston, TX 77030, USA
    Leuk Res 27:1077-83. 2003
  10. ncbi request reprint Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, P O Box 428, Houston, TX 77030, USA
    Leuk Res 27:1091-6. 2003

Research Grants

  1. Phase I Clinical Trials of Anti-Cancer Agents
    Francis Giles; Fiscal Year: 2007
  2. Phase I Clinical Trials of Anti-Cancer Agents
    Francis Giles; Fiscal Year: 2007

Collaborators

Detail Information

Publications125 found, 100 shown here

  1. ncbi request reprint The role of inflammation in leukaemia
    Francis J Giles
    Northwestern Medicine Developmental Therapeutics Institute, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
    Adv Exp Med Biol 816:335-60. 2014
    ....
  2. pmc Targeting HSP90 for cancer therapy
    D Mahalingam
    Institute for Drug Development, Cancer Research and Therapy Centre at the University of Texas Health Science Centre, San Antonio, TX 78229, USA
    Br J Cancer 100:1523-9. 2009
    ..We also highlight the key oncogenic proteins that are regulated by HSP90 and describe how inhibition of HSP90 could alter the activity of multiple signalling proteins, receptors and transcriptional factors implicated in carcinogenesis...
  3. pmc Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
    Ronan Swords
    Institute for Drug Development, Cancer Therapy and Research Centre, University of Texas Health Science Centre at San Antonio, 7979 Wurzbach Road, San Antonio, TX 78229, USA
    Drug Des Devel Ther 3:89-101. 2009
    ..The purpose of this review is to summarize the pre-clinical and clinical data on nilotinib in patients with CML who have failed prior therapy with IM or dasatinib...
  4. doi request reprint Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
    F J Giles
    HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, Dublin, Ireland
    Leukemia 27:1310-5. 2013
    ....
  5. doi request reprint MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia
    F J Giles
    HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College Dublin, Galway, Ireland
    Leukemia 27:113-7. 2013
    ..MK-0457 has important activity in patients with leukemias expressing the highly resistant T315I BCR-ABL mutation...
  6. doi request reprint Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    F J Giles
    HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College, Dublin, Ireland
    Leukemia 27:107-12. 2013
    ..Further significant improvements in therapy are required for patients who are resistant or intolerant to imatinib...
  7. doi request reprint Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia
    Francis Giles
    HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, Dublin, Ireland
    Eur J Clin Invest 42:1016-26. 2012
    ..imatinib...
  8. doi request reprint Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
    F J Giles
    HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, University Road, Galway, Ireland
    Leukemia 26:959-62. 2012
    ..Nilotinib has significant efficacy in patients with BP CML, but given the limited long-term survival of these patients, novel agents are needed...
  9. ncbi request reprint Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Box 428, Houston, TX 77030, USA
    Leuk Res 27:1077-83. 2003
    ..Based on these clinical, pharmacokinetic, and pharmacodynamic data, Triapine warrants further study in patients with hematologic malignancies...
  10. ncbi request reprint Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, P O Box 428, Houston, TX 77030, USA
    Leuk Res 27:1091-6. 2003
    ..Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML...
  11. ncbi request reprint Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 100:1449-58. 2004
    ..OSI-211 is a low-clearance, unilamellar liposomal formulation of a water-soluble camptothecin analogue, lurtotecan. OSI-211 has significant activity in severe combined immunodeficient mouse models of human leukemia...
  12. ncbi request reprint Novel therapies for patients with chronic myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 4:271-82. 2004
    ....
  13. ncbi request reprint A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, The University of Texas, Box 428, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 28:353-7. 2004
    ..Six patients (35%) achieved complete remission. Seven patients (41%) developed grade 3 or 4 diarrhea. FTA was effective and warrants further study in patients with refractory AML...
  14. ncbi request reprint A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy
    Francis J Giles
    M D Anderson Cancer Center, Department of Leukemia, The University of Texas, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 28:559-65. 2004
    ..A major impact of Iseganan on reducing stomatitis, UOM, or its clinical sequelae in patients receiving stomatotoxic therapy was not detected on this study...
  15. ncbi request reprint Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 11:7817-24. 2005
    ..A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease...
  16. ncbi request reprint New drugs in acute myeloid leukemia
    Francis J Giles
    Section of Developmental Therapeutics, Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Curr Oncol Rep 4:369-74. 2002
    ..Those agents targeting vascular endothelial growth factor are also briefly reviewed...
  17. ncbi request reprint Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions
    Francis J Giles
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Pharmacother 37:1182-5. 2003
    ..To assess whether the addition of a brief course of intravenous corticosteroids reduces the incidence of infusion-related adverse events associated with gemtuzumab ozogamicin (GO) administration...
  18. ncbi request reprint A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial)
    Francis J Giles
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Leuk Lymphoma 44:1165-72. 2003
    ..6 and 2.0 (P = 0.0131). Iseganan was well tolerated; no systemic absorption was detected. Iseganan is safe and may be effective in reducing UOM and its clinical sequelae...
  19. ncbi request reprint Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:1050-6. 2003
    ..Troxacitabine has significant single-agent activity. This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan...
  20. ncbi request reprint SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:795-801. 2003
    ..Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML/MDS...
  21. ncbi request reprint Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 2:630-40. 2002
    ..Gemtuzumab ozogamicin-based combinations should not be prescribed outside the research setting until further data is available...
  22. ncbi request reprint Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:1920-8. 2003
    ..SU5416 is a small-molecule RTK inhibitor (RTKI) that targets VEGFR-2, c-kit, and fms-related tyrosine kinase Flk2...
  23. ncbi request reprint Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:1722-7. 2003
    ..A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy...
  24. ncbi request reprint Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 52:223-8. 2003
    ..The combination of fludarabine and cyclophosphamide (FC) is highly active in patients with chronic lymphocytic leukemia (CLL). Infection is a serious toxicity of the FC regimen...
  25. ncbi request reprint Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome
    Francis Giles
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Acta Haematol 108:164-7. 2002
  26. ncbi request reprint Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival
    Francis J Giles
    Department of Leukaemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 119:38-45. 2002
    ..0002, Cox proportional hazard model). A multivariate model based on Cox-2 and degree of splenomegaly was developed for survival in patients with early CP CML. Agents that inhibit Cox-2 activity merit investigation in patients with CP CML...
  27. ncbi request reprint Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Mol Med 5:615-23. 2005
    ..We review the current data on imatinib in CML, the criteria for diagnosis of imatinib resistance, and the mechanisms that underlie such resistance in CML...
  28. ncbi request reprint The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:801-11. 2006
    ..AG-01736 had minimal biologic or clinical activity in this elderly patient population...
  29. ncbi request reprint Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, 77230 1402, USA
    Br J Haematol 134:58-60. 2006
    ..The EPI is reproducible and useful...
  30. ncbi request reprint Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    F J Giles
    Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Leukemia 23:1698-707. 2009
    ..This paper reviews the various kinases inhibited by imatinib, nilotinib and dasatinib, and describes the potential impact of kinase inhibition on the efficacy and safety of each agent...
  31. ncbi request reprint New directions in the treatment of imatinib failure and/or resistance
    Francis J Giles
    Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Semin Hematol 46:S27-33. 2009
    ....
  32. ncbi request reprint Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse
    Francis Giles
    Cancer Therapy and Research Center CTRC at The University of Texas Health Science Center, San Antonio, TX 78229, USA
    Blood 114:4027-33. 2009
    ..The DSMB subsequently approved a revised protocol with laromustine dose reduction and recombinant growth factor support. The study was registered as NCT00112554 at http://www.clinicaltrials.gov...
  33. pmc Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
    F J Giles
    Cancer Treatment and Research Center at The University of Texas Health Science Center, Institute for Drug Development, San Antonio, TX 78229, USA
    Leukemia 24:1299-301. 2010
    ..Nilotinib is an effective therapy in CML-CP and -AP following failure of both imatinib and dasatinib therapy...
  34. ncbi request reprint Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study
    Francis J Giles
    HRB Clinical Research Facility, National University of Ireland, Galway and Trinity College, Dublin, Ireland
    Expert Rev Hematol 3:665-73. 2010
    ..Nilotinib's clinical superiority over imatinib, as demonstrated by the ENESTnd study, has established it as an agent that we believe is a significant further step towards the cure of CML...
  35. ncbi request reprint Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia
    F J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    J Clin Oncol 19:762-71. 2001
    ..To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia...
  36. ncbi request reprint A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study
    F J Giles
    International Oncology Study Group, Houston, Texas, USA
    Leuk Lymphoma 40:95-103. 2000
    ....
  37. ncbi request reprint A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study
    F J Giles
    The International Oncology Study Group, Houston, Texas 77401, USA
    Leuk Lymphoma 37:367-77. 2000
    ..In conclusion if seems that there is no apparent early survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as first-line CML therapy...
  38. doi request reprint Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia
    Francis J Giles
    Professor of Medicine, and Chief, Division of Hematology and Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Semin Oncol 35:S1-17; quiz S18-20. 2008
    ..Other areas such as microRNA profiling and DNA methylation patterns are likely to provide important information...
  39. ncbi request reprint Plasma-based testing as a new paradigm for clinical testing in hematologic diseases
    Francis J Giles
    University of Texas Health Science Center, Division of Hematology and Medical Oncology, San Antonio, TX 78229, USA
    Expert Rev Mol Diagn 7:615-23. 2007
    ..Unlike solid tumors, currently available data suggest that in hematologic diseases, plasma is superior to cells in detecting molecular abnormalities...
  40. ncbi request reprint A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Francis Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4628-35. 2006
    ..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
  41. ncbi request reprint Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML
    Francis J Giles
    Division of Hematology and Medical Oncology, San Antonio, TX 78229, USA
    Leuk Lymphoma 48:1064-6. 2007
  42. ncbi request reprint MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, 1400 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 109:500-2. 2007
    ..The observation of responses in 3 patients with T315I phenotype-refractory CML or Ph-positive ALL, at doses of MK-0457 associated with no significant extramedullary toxicity, is very encouraging...
  43. ncbi request reprint Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia
    Francis Giles
    The University of Texas M D Anderson Cancer Center, Department of Leukemia, Houston, TX 77030, USA
    J Clin Oncol 25:25-31. 2007
    ..A multicenter phase II study of cloretazine was conducted in patients 60 years of age or older with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)...
  44. ncbi request reprint The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
    Francis J Giles
    Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 136:624-7. 2007
    ..001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy...
  45. ncbi request reprint PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia
    Francis J Giles
    The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 31:891-7. 2007
    ..One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM...
  46. ncbi request reprint Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol
    F J Giles
    The International Oncology Study Group, Houston, Texas 77401, USA
    Am J Hematol 63:125-30. 2000
    ..In 15% of septic episodes positive blood cultures were obtained. Overt cardiotoxicity was seen in two patients. CEVAD as used in this study was not more effective than VAD in terms of overall response rate or survival...
  47. ncbi request reprint High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens
    M Beran
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 92:1999-2015. 2001
    ..Because the results of standard regimens have been disappointing, high-dose chemotherapeutic regimens were investigated recently. In the absence of randomized trials, the relative merits of various treatment regimens are unknown...
  48. ncbi request reprint Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia
    E H Estey
    Department of Leukemia Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 94:2230-5. 1999
    ..Our data suggest that lipoATRA is an effective means of producing molecular CR in newly diagnosed APL...
  49. ncbi request reprint Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase
    F J Giles
    Department of Leukemia; University of Texas MD Anderson Cancer Center Houston, Texas 77030, USA
    Leuk Lymphoma 41:309-19. 2001
    ..01). In conclusion, the addition of intensive chemotherapy may improve survival in patients with CML who have not obtained an adequate cytogenetic response on an IFN-alpha-based regimen...
  50. ncbi request reprint Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
    E H Estey
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 98:3575-83. 2001
    ..It is unlikely that, as given here, either FA or TA is, in general, superior to IA, highlighting the need for new treatments...
  51. ncbi request reprint Antiangiogenic therapy in leukemia
    D A Thomas
    Department of Leukemia, M D Anderson Cancer Center, Houston, Tex 77030, USA
    Acta Haematol 106:190-207. 2001
    ..The role of angiogenesis in hematological malignancies, the rationale for the use of angiosuppressive therapy for these entities, and the status of novel antiangiogenic agents in clinical trials are discussed...
  52. ncbi request reprint Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
    H M Kantarjian
    Leukemia Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:1414-20. 2001
    ..Myelosuppression and infection remain the most significant complications of therapy in CLL...
  53. ncbi request reprint High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome
    S Verstovsek
    Department of Leukemia, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Leuk Lymphoma 42:511-6. 2001
    ..The role of Tie-1 overexpression in the reported increased vascularity in the bone marrow of AML and MDS patients requires further investigation...
  54. ncbi request reprint Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
    Apostolia Tsimberidou
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Leuk Res 27:893-7. 2003
    ..CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML...
  55. ncbi request reprint Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 50:497-500. 2002
    ..Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML...
  56. ncbi request reprint Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
    F J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 92:406-13. 2001
    ..Hepatic venoocclusive disease (VOD) has been reported in patients who have undergone stem cell transplantation (SCT) after Mylotarg therapy. Outside of the SCT setting, VOD has been associated very rarely with cytotoxic therapy...
  57. ncbi request reprint Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome
    B S Dabaja
    Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, Texas 77030, USA
    Leuk Lymphoma 42:329-37. 2001
    ..0017). In conclusion the hyper CVXD regimen has a relatively high response rate, significant toxicity and a moderate impact on survival in RS...
  58. ncbi request reprint Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome
    S Verstovsek
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Leukemia 15:1165-70. 2001
    ..No significant correlation was observed between HGF levels and complete remission rate or duration. In the multivariate analysis HGF retained its significance as prognostic factor in AML (P = 0.02), along with age (P = 0.0005)...
  59. ncbi request reprint Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase
    H M Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 92:2501-7. 2001
    ..The association of treatment response with survival was evaluated by multivariate and landmark analyses...
  60. ncbi request reprint The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies
    F J Giles
    Department of Leukemia, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 6:32-9. 2001
    ....
  61. ncbi request reprint Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
    Elihu H Estey
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:4343-9. 2002
    ..Thus, there is little evidence to suggest that GO with or without IL-11 should be used instead of IA in older patients with newly diagnosed AML or myelodysplastic syndrome...
  62. pmc Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism
    H Zhang
    Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 22:1191-9. 2008
    ..Our results suggest that PEITC is a promising compound capable of killing Gleevec-resistant CML cells through a ROS-mediated mechanism and warrants further investigations...
  63. ncbi request reprint Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias
    H M Amin
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Leukemia 19:1567-72. 2005
    ..These data also suggest that MDS classification schemes should take into account the percentage of blasts in PB differently from the percentage of blasts in BM...
  64. ncbi request reprint Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
    M Beran
    Departments of Leukemia and Molecular Hematology, and Division of Laboratory Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:2819-30. 1999
    ..To evaluate the efficacy and safety of the combination of topotecan and cytarabine in patients with myelodysplastic syndromes (MDSs) and chronic myelomonocytic leukemia (CMML)...
  65. ncbi request reprint Rituximab dose-escalation trial in chronic lymphocytic leukemia
    H Kantarjian
    Leukemia Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:2165-70. 2001
    ..Efficacy of rituximab was also significant in this group of patients...
  66. ncbi request reprint Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
    H M Kantarjian
    Departments of Leukemia, Bioimmunotherapy, Biostatistics, and Blood and Bone Marrow Transplantation, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 18:3513-21. 2000
    ....
  67. doi request reprint Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma
    K R Kelly
    Department of Medicine, The Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX 78229, USA
    Oncogene 31:3023-38. 2012
    ..Furthermore, reovirus infection can be used as a promising approach to augment the anti-myeloma activity of bortezomib by promoting additional stress to the endoplasmic reticulum of MM cells...
  68. ncbi request reprint Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival
    F J Giles
    Departments of Leukemia, Biostatistics, and Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 61, Houston, TX 77030, USA
    Leuk Lymphoma 42:67-73. 2001
    ....
  69. ncbi request reprint Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance
    F Ravandi
    Department of Leukemia, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 91:1964-72. 2001
    ..The influence of these cellular proteins and caspase-3 activity on apoptosis in CML is complex and merits further investigation...
  70. ncbi request reprint Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia
    J R Beck
    Information Technology Program, Baylor College of Medicine, Houston, Texas 77030, USA
    Leuk Lymphoma 41:117-24. 2001
    ..Based on data from the French study, cytarabine added to IFN-alpha substantially improves the cost-effectiveness of initial therapy for early chronic phase CML...
  71. ncbi request reprint Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome
    Srdan Verstovsek
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 118:151-6. 2002
    ..These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS...
  72. ncbi request reprint Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 108:45-51. 2006
    ..However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation...
  73. ncbi request reprint Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2134-41. 2002
    ....
  74. ncbi request reprint Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:813-22. 2006
    ..The recommended phase II regimen is Triapine 105 mg/m2/day followed by ara-C 600 mg/m2/day for 5 consecutive days every 3-6 weeks...
  75. ncbi request reprint The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1
    J Pan
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 21:1395-404. 2007
    ..Our data establish EXEL-0862 as a solid candidate for the targeted treatment of patients with FIP1L1-PDGFR-alpha-positive HES...
  76. pmc Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
    D Mahalingam
    Department of Medicine, Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, 7979 Wurzbach Road, San Antonio, TX 78245, USA
    Br J Cancer 105:1563-73. 2011
    ..We hypothesised that inhibition of PIM kinase activity with SGI-1776, a novel small molecule inhibitor of PIM kinase activity, would reduce the viability of renal cell carcinoma (RCC) cells and enhance the activity of sunitinib...
  77. ncbi request reprint Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 52:449-52. 2003
    ..The Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen was evaluated in patients in complete remission following Mylotarg-containing regimens...
  78. ncbi request reprint Troxacitabine-based therapy of refractory leukemia
    Francis J Giles
    Section of Developmental Thereputics, The University of Texas M D Anderson Cancer Center, Department of Lukemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030 4095, USA
    Expert Rev Anticancer Ther 2:261-6. 2002
    ..Phase II studies in patients with refractory lymphoproliferative diseases are ongoing. Troxacitabine merits further study in patients with hematological malignancies...
  79. ncbi request reprint Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
    Yesid Alvarado
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Cancer Chemother Pharmacol 51:87-90. 2003
    ..A combination of an anthracycline and cytarabine (ara-C) is the core of most AML induction regimens. We conducted a pilot study of Mylotarg combined with idarubicin and ara-C in patients with refractory or relapsed AML...
  80. ncbi request reprint Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
    Alvaro Aguayo
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 95:1923-30. 2002
    ..Increased levels in urine, serum, plasma, or malignant tissue have been associated with an adverse prognosis in patients with solid tumors...
  81. ncbi request reprint Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
    Stefan Faderl
    Department of Leukemia, Box 428, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 105:940-7. 2005
    ..The combination of clofarabine with ara-C is safe and active. Cellular pharmacology data support the biochemical modulation strategy...
  82. ncbi request reprint Therapeutic choices in younger patients with chronic myelogenous leukemia
    H M Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 89:1647-58. 2000
    ..Both therapies may be suitable for younger patients. The authors reviewed current data to assist in prioritizing these modalities in an individual patient...
  83. ncbi request reprint Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia
    F J Giles
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 37:87-95. 2000
    ..We conclude that oral idarubicin is sufficiently safe and active to warrant phase II studies investigating it as part of interferon-based regimens in patients with advanced CML...
  84. ncbi request reprint Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia
    M Talpaz
    Department of Bioimmunotherapy, M. D. Anderson Cancer Center, Houston, TX, USA
    Blood 98:1708-13. 2001
    ..The results show that PEG IFN-alpha-2b is easier to deliver (once weekly), better tolerated, and perhaps more effective than IFN-alpha...
  85. ncbi request reprint Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
    Dan Jones
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:985-94. 2008
    ..Patterns of KD mutations in Philadelphia chromosome (Ph)-positive acute lympho- blastic leukemia (ALL) are less well studied...
  86. ncbi request reprint The role of gemtuzumab ozogamicin in acute leukaemia therapy
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 132:398-409. 2006
    ..The future of GO is its use in combination with other cytotoxic agents. Ongoing clinical trials may better define the role of GO combinations, particularly in untreated AML...
  87. ncbi request reprint Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment
    Apostolia Maria Tsimberidou
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Leuk Res 27:375-80. 2003
    ..No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study...
  88. ncbi request reprint New agents in myelodysplastic syndromes
    Elias J Jabbour
    Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77063, USA
    Curr Hematol Rep 4:191-9. 2005
    ..Further development of rational therapies and improvements in the outcome of patients with MDS are likely to emerge from an increased understanding of the pathophysiology of these diseases...
  89. ncbi request reprint Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
    ..Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed...
  90. ncbi request reprint Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Blood 101:3413-5. 2003
    ..The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses...
  91. ncbi request reprint Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 100:1590-5. 2002
    ..We conclude that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD...
  92. ncbi request reprint Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:6615-24. 2005
    ..A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...
  93. ncbi request reprint Troxacitabine activity in extramedullary myeloid leukemia
    Yesid Alvarado
    Department of Leukemia, M D Anderson Cancer Center, The University of Texas, Houston 77030, USA
    Hematology 7:179-85. 2002
    ..Troxacitabine-based therapy had significant antileukemic activity in extramedullary myeloid leukemias and warrants further investigation in this clinical situation...
  94. ncbi request reprint The emerging role of angiogenesis inhibitors in hematologic malignancies
    Francis J Giles
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 16:23-9. 2002
    ..This review will summarize several angiogenesis inhibitors in clinical development...
  95. ncbi request reprint Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy
    Jennifer S Carew
    The Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, 14960 Omicron Drive, San Antonio, TX 78245, USA
    Cancer Lett 269:7-17. 2008
    ..Here we summarize the different mechanisms of HDAC inhibitor-induced apoptosis and discuss their use in combination with other anticancer agents...
  96. ncbi request reprint Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:656-64. 2002
    ..To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia...
  97. ncbi request reprint Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia
    Efrosyni Apostolidou
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Box 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Leuk Res 27:887-91. 2003
    ..The inclusion of CSA in a gemtuzumab ozogamicin-containing regimen is feasible. The MDAC regimen was associated with significant toxicity in a cohort of patients with very advanced AML...
  98. ncbi request reprint Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
    Karen W L Yee
    Authors Affiliations Departments of Leukemia and Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 12:5165-73. 2006
    ..A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malignancies...
  99. ncbi request reprint Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3547-53. 2002
    ..04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML...
  100. ncbi request reprint Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
    ..Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens...
  101. ncbi request reprint Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2167-76. 2002
    ..Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML)...

Research Grants2

  1. Phase I Clinical Trials of Anti-Cancer Agents
    Francis Giles; Fiscal Year: 2007
    ..abstract_text> ..
  2. Phase I Clinical Trials of Anti-Cancer Agents
    Francis Giles; Fiscal Year: 2007
    ..abstract_text> ..